Summary

Pseudomyxoma peritonei (PMP) is a rare disease and even after advances in its understanding and management it often has a protracted course and multiple recurrences despite aggressive surgery and intraperitoneal chemotherapy. The current preferred treatment of ultraradical surgery and hyperthermic intraperitoneal chemotherapy is associated with considerable morbidity and significant mortality. With better understanding we know that the prognosis of the disease is dependent on the degree of total excision of the disease and type of histology. The authors propose the need to be selective in applying aggressive treatment regimens in all patients with PMP regardless of factors like age, low malignant variants and expected morbidities. Our patient had a good outcome with a conservative approach. However, large studies are needed before reaching a conclusion.